Osteoporosis in patients under oral anticoagulant treatment;Osteoporose bei patienten unter oraler antikoagulantien-therapie

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 50, 2004, Pages 2707-2710

  Liebig, S ^a   Stracke, H ^a   Nees, M ^a   Kemkes Matthes, B ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CALCIFEDIOL; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; ESTRADIOL; HYDROCORTISONE; PARATHYROID HORMONE; PHENPROCOUMON; TESTOSTERONE; VITAMIN D; WARFARIN;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; INCIDENCE; MALE; OSTEOPOROSIS; X RAY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; TIME FACTORS; VITAMIN D;

EID: 11144291504     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-836097     Document Type: Article

References (29)

1. Akjba T, Kurihara S, Tachibana K et al. Vitamin K (K) increased bone mass (BM) in hemo-dialysis patients (pts) with low-turnover bone disease, (LTOBD). J Am Soc Nephrol 1991; 608: 42P
2. Alban S. Der Thrombosegefahr vorbeugen. Regensburg, 2002
3. Barthel HR, Scharla SH. Mehr als nur Knochenschutz - Vitamin D zur Prevention von Stürzen, Krebs, Bluthochdruck und Autoimmunerkrankungen. Dtsch Med Wochenschr 2003; 128: 440-446
4. Binkley N, Krueger D. Osteoporosis in men. WMJ 2002; 101: 28
5. Binkley NC, Suttie JW. Vitamin K nutrition and osteoporosis. J Nutr 1995; 125: 1812
6. Boskey AL, Gadaleta S, Gundberg C et al. Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 1998; 23: 187
7. Bugel S. Vitamin K and bone health. Proc Nutr Soc 2003; 62: 839-843
8. Carol L. Osteoporosis and men. FDA Consum 2002; 36: 15-17
9. Craciun AM, Wolf J, Knapen MHJ, Brouns F, Vermeer C. Improved bone metabolism in female elite athlets after vitamin K supplementation. Int Sports Med 1998; 19: 479
10. Diamond T, Sambrook P, Williamson M, Flicker L et al. Men and osteoporosis. Aust Fam Physician 2001; 30: 781
11. Ducy P, Desbois C, Boyce B et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448
12. Faßbender WJ, Scheidt-Nave Ch, Pfeilschifter J. Die neuen Leitlinien zur Osteoporose. Empfehlungen des Dachverbandes der deutschsprachigen osteologischen Fachgesellschaften. Dtsch Med Wochenschr 2003; 128; 1615-1616
13. Faßbender WJ, Usadel KH. Die Osteoporose ist eine Volkskrankheit - Evidenzbasierte Leitlinien wurden verabschiedet. Dtsch Med Wochenschr 2003; 128: 915
14. Fiore CD, Tamburino C, Foti R, Grimaldi D. Reduced bone mineral content in patients taking an oral anticoagulant. South Med J 1990; 83: 538
15. Ishida Y, Soh H, Ogawa S, Kawahara, Murata H. A one-year randomized controlled trial of hormone replacement therapy, bisphosphonate, calcitonin, vitamin D and vitamin K in women with postmenopausal osteoporosis. J Bone Miner Res 2000; 15: S310(suppl 1
16. Ismail A, Cooper C, Felsenberg D et al. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European vertebral osteoporosis study group. Osteoporos Int 1999; 9: 206-213
17. Khosla S, Kleerekoper M. Boichemical markers of bone turnover. 4th ed (Hrsg). Philadelphia: Lippincott Williams&Wilkins, In: Favus MJ.ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 1999: 128
18. Kudlacek S, Schneider B, Resch H, Freudenthaler O, Willvonseder R. Gender differences in fracture risk and bone mineral density. Maturitas 2000; 36: 173-180
19. Orimo H, Shiraki M, Tomita A et al. Effects of menatretenone on the bone and calcium in osteoporosis: a double-blind placebo-controlled study. J Bone Miner Metab 1998; 16: 106
20. Pihusch R, Die Therapie mit oralen Cumarin-Derivaten. Medizinische Klinik III, Hämostaseologie Klinikum Großhadern, München, 1993
21. Piro LD, Whyte MP, Murphy WA, Birge SJ. Normal cortical bone mass in patients after long term coumadin therapy. J Clin Endocrinol Metab 1982; 54: 470
22. Rosen HN, Maitland LA, Suttie JW et al. Vitamin K and maintenance of skeletal integrity in adults. Am J Med 1993; 94: 62
23. Sakamoto N, Nishiike T, Iguchi H, Sakamoto K. The effect of diet on blood vitamin K status and urinary mineral excretion assessed by a food questionnaire. Nutr Health 1999; 13: 1
24. Sato Y, Honda Y, Kuno H, Oizumi K. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 1998; 23: 291
25. Schneider P, Schütze N, Jakob F. Genetik der Osteoporose. Dtsch Med Wochenschr 2003; 128: 2216
26. Schütze N, Ebert R, Paunescu K, Jakob F. Genetik der Osteoporose. Dtsch Med Wochenschr 2003; 128: 1609-1614
27. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (Menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000; 15: 515
28. Weber P. Vitamin K and bone health. Nutrition 2001; 17: 880
29. Yonemura K, Kimura M, Miyaji T, Hishida A. Short-trem effect of vitamin K administration on prednisolone-induced bone loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int 2000; 66: 123